Live Discussion & Question Time

Time: 12:00 pm
day: Day One


  • What are the clinical cross-learnings for JAK inhibitor application across both blood-related disorders and immune-mediated diseases?
  • How can we refine clinical trial protocols to include clinically meaningful biomarkers with improved predictability of patient response and clinically meaningful endpoints?
  • In what clinical indications do effective combination regimens that include JAK inhibitors play a role and how can these combinations be optimized?